ArticleAnimal models and experimental medicine2025
Two-stage portal flow modulation for volume-augmented grafts in living donor liver transplantation: Rat model validation.
Article in Animal models and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Two-stage portal flow modulation for volume-augmented grafts in living donor liver transplantation: Rat model validation.Animal models and experimental medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Graft procurement in adult living donor liver transplantation (LDLT) faces persistent challenges in balancing volumetric adequacy and donor safety. This study introduces two-stage portal vein ligation and reperfusion for graft procurement in LDLT (PVLR-LT), which aims to expand the left lateral lobe for achieving adequate grafts, thereby circumventing technical and anatomical limitations of conventional approaches. In a rat model, the PVLR-LT group underwent selective portal vein ligation (step I) to induce targeted hypertrophy, followed by reperfusion and transplantation (step II). Outcomes were compared among PVLR-LT, negative controls, and standard-volume controls. Staged portal flow modulation effectively redistributed hepatic mass allocation, yielding grafts with graft recipient weight ratio approximately double that of negative controls and equivalent to standard-volume controls. Donors experienced no mortality, with only transient enzyme elevation. Recipient survival in the PVLR-LT group significantly exceeded that of the negative control group and was non-inferior to that of the standard-volume control group, while hepatic enzyme peaks were markedly lower than those in standard-volume control recipients. This study provides a promising proof of concept, establishing the feasibility of using PVLR-LT to convert the surgically straightforward left lateral segment into right lobe-sized grafts through staged portal flow modulation and demonstrating the translational potential for laparoscopic LDLT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.